# OnCo record nab-paclitaxel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nab-paclitaxel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nab-paclitaxel" ;
  schema:name "Nab-paclitaxel"@en ;
  schema:description "Paclitaxel bound to albumin so it needs no solvent and no steroid premedication. Adding it to gemcitabine and cisplatin looked promising in a small study of bile duct and gallbladder cancer but did not lengthen life in the 452-patient SWOG S1815 trial."@en ;
  schema:url <https://onco.cc/drugs/nab-paclitaxel/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Protein-bound_paclitaxel> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4>, <https://doi.org/10.1200/JCO-24-01383>, <https://doi.org/10.1001/jamaoncol.2019.0270> ;
  onco:status "approved" ;
  onco:modality "Albumin-bound taxane (cytotoxic)" ;
  schema:alternateName "Abraxane" ;
  onco:approval "US 2005: Metastatic breast cancer after combination chemotherapy", "EU 2008: Metastatic breast cancer; later pancreatic (2013) and non-small-cell lung cancer (2015)", "US 2013: First-line metastatic pancreatic adenocarcinoma with gemcitabine (MPACT)" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/swog-s1815/>, <https://onco.cc/trials/gap-phase2-mdacc/>, <https://onco.cc/trials/rugb/> .